


















of	 aggressive	 B-NHL	 occurs	 frequently,	 which	 may	 coincide	 with	 therapy	 resistance.	 This	
demonstrates	 the	 urgent	 need	 for	 exploring	 new	 lymphoma-targeted	 therapies.	 Here,	we	









marrow	 towards	 ultimately	 the	 differentiation	 into	 antibody-producing	 plasma	 cells	 and	
memory	B	cells.	Upon	encountering	specific	antigens,	germinal	centers	(GC,	see	Glossary)	are	
formed	within	 the	 lymph	 node,	where	 B	 cells	 undergo	 somatic	 hypermutation	 (SHM,	 see	
Glossary)	 and	 class	 switch	 recombination	 (CSR,	 see	 Glossary)	 in	 order	 to	 generate	 a	 high	
affinity	B-cell	receptor	(BCR).	However,	SHM	and	CSR	are	error-prone	mechanisms,	hence	the	







The	 GC-derived	 B-NHLs	 include	 follicular	 lymphoma	 (FL,	 see	 Glossary),	 Burkitt	
lymphoma	(BL,	see	Glossary),	and	diffuse	large	B-cell	lymphoma	(DLBCL,	see	Glossary).	DLBCL	






large	 proportion	 of	 FL	 cases	 the	 disease	 transforms	 into	 the	 more	 aggressive	 DLBCL	 [6].	
Current	 first-line	 treatment	 of	 DLBCL	 consists	 of	 the	 combination	 of	 rituximab	 (anti-CD20	
monoclonal	 antibody	 (mAb))	 with	 CHOP-based	 (see	 Glossary)	 chemotherapy,	 frequently	
followed	 by	 subsequent	 radiotherapy.	 BL	 is	 treated	 with	 CHOP-based	 chemotherapy,	
sometimes	combined	with	rituximab.	For	FL,	a	watch-and-wait	policy	is	frequently	applied.	In	
case	of	treatment	indication,	first-line	treatment	consists	of	rituximab	combined	with	CHOP-	
or	CVP-based	 (see	Glossary)	 chemotherapy	with	or	without	 subsequent	 radiotherapy.	 The	
exact	protocol	depends	on	the	diagnosis	and	condition	of	the	patient	[7–9].	
Although	 immunotherapy	 with	 rituximab	 has	 significantly	 improved	 the	 clinical	
outcome	of	patients	with	B-cell	malignancies	[10,11],	many	patients	with	DLBCL	[12],	BL	[11]	
and	 FL	 [13]	 suffer	 from	 treatment	 failure	 or	 relapse.	 Several	 novel	 targeted	 therapies	 are	
currently	 under	 (pre-)clinical	 investigation,	 including	 therapies	 targeting	 the	 tumor	






successful	 antibody-based	 immunotherapy	 targeting	 a	membrane	protein.	 Antibody-based	
membrane-targeted	therapies	act	through	different	mechanisms,	including	direct	cell	death	
signaling,	 antibody-dependent	 cell-mediated	 cytotoxicity	 (ADCC,	 see	 Glossary)	 and	
complement-dependent	cytotoxicity	(CDC,	see	Glossary).	In	this	review,	we	focus	on	recent	














Anti-CD20	mAbs	 have	 been	 classified	 as	 type	 I	 and	 type	 II	 [18],	which	 both	 induce	
ADCC.	 Type	 I	 mAbs	 (e.g.	 rituximab	 and	 ofatumumab)	 are	 regarded	 as	 the	 most	 potent	
antibodies	 because	 of	 their	 capacity	 to	 initiate	 CDC	 in	 contrast	 to	 type	 II	 mAbs	 (e.g.	
obinutuzumab).	Furthermore,	type	II	mAbs	may	induce	direct	cell	death	(Figure	1b),	although	
the	 exact	 mechanism	 remains	 to	 be	 elucidated.	 Upon	 type	 I	 mAb	 binding,	 CD20	 is	









Besides	 CD20,	 numerous	 other	 potential	 membrane	 targets	 have	 been	 investigated	 in	
lymphoma	including:	CD19,	CD22,	CD23,	CD37,	CD47,	CD52,	CD74,	CD79α,	CD80,	HLA-DR,	and	
the	BCR	(idiotype).	Furthermore,	immune	checkpoint	inhibitors	that	target	programmed	cell	
death	 protein	 1	 (PD-1)	 and	 programmed	 cell	 death	 ligand	 1	 (PD-L1)	 are	 currently	 in	 the	
spotlight	for	treatment	of	B-NHL.	Targeting	of	some	of	these	cell	surface	proteins	with	mAbs	
has	 shown	promising	 therapeutic	 efficacy,	 but	 targeting	others	 seems	 less	 suitable	due	 to	
limited	 specificity	 (e.g.	 CD80	 and	 HLA-DR	 are	 very	 broadly	 expressed)	 or	 resistance	
development	 (e.g.	 due	 to	 antigen	 shedding	 or	 internalization).	 A	 few	 new	mAbs	 directed	
against	B-cell	surface	proteins	currently	tested	in	clinical	trials	show	promising	results	either	
as	first-line	therapy	in	combination	with	rituximab,	or	as	monotherapy	for	heavily-pretreated	













Igα)	 and	CD79β	 (or	 Igβ)	which	both	 contain	 an	 immunoreceptor	 tyrosine-based	 activation	
motif	 (ITAM)	 to	 transmit	 intracellular	 signaling.	 Upon	 antigen	 binding,	 the	 conformational	
state	 of	 the	 BCR	 changes	 to	 initiate	 downstream	 signaling,	 but	 the	 underlying	 molecular	
mechanisms	 are	 still	 debated.	 The	 “conformation-induced	oligomerization	model”,	 which	
proposes	 that	 single	 BCRs	 oligomerize	 upon	 antigen	 recognition	 [21],	 has	 recently	 been	
challenged	 by	 super-resolution	 studies.	 This	 has	 led	 to	 convincing	 evidence	 for	 the	
“dissociation-activation	 model”,	 in	 which	 BCR	 oligomers	 dissociate	 upon	 antigen	 binding,	
gaining	an	open	conformation	[22,23].	This	conformational	change	influences	the	distribution	
of	BCR	co-receptors	CD19	and	CD20	that	interact	with	IgD	oligomers	on	resting	B	cells,	and	
relocate	 to	 IgM	oligomers	upon	B-cell	activation	 [23].	These	changes	 in	plasma	membrane	
organization	 are	 controlled	 by	 a	 superfamily	 of	 membrane-organizing	 proteins,	 called	
tetraspanins	 (Box	 2).	 Tetraspanin	 CD81	 is	 required	 for	 reorganization	 of	 CD19	 to	 BCR	
nanoclusters,	which	enables	binding	of	signaling	proteins	to	the	intracellular	domain	of	CD19	
and	initiation	of	signaling	downstream	of	the	BCR	[24,25].	
Two	modes	of	BCR	 signaling	have	been	described:	 1)	 active	 signaling	upon	antigen	
binding	to	the	BCR	leading	to	NF-κB	activation	via	Syk,	phosphoinositide	3-kinase	(PI3K)	and	
Bruton’s	 tyrosine	 kinase	 (BTK);	 and	 2)	 tonic	 signaling,	 an	 antigen-independent	mechanism	
required	for	B-cell	survival	which	occurs	in	mature	resting	B	cells	via	activation	of	PI3K	and	
protein	kinase	B	(AKT)	(reviewed	in	[26])	(Figure	1c).	In	most	GC-derived	B-cell	lymphomas,	





DLBCL	 which	 is	 evidenced	 by	 knockdown	 experiments	 of	 BTK	 or	 components	 of	 the	 BCR	
complex	 that	 induced	 killing	 of	 lymphoma	 cells	 [4].	 In	 contrast,	GCB-DLBCL	 cells	were	not	
killed,	indicating	they	do	not	require	BCR	signaling	to	survive.	In	the	majority	of	ABC-DLBCL	



























promising	 to	 treat	 B-NHL	 patients	 [38],	 which	 is	 currently	 investigated	 in	 clinical	 trials	
(https://clinicaltrials.gov/).		
Therapeutic	 strategies	 targeting	 the	 BCR	 co-receptor	 CD19	 are	 encouraging	 for	
patients	with	relapsed/refractory	B-NHL.	CD19	chimeric-antigen	receptors	expressed	by	T	cells	
(CD19-CAR	T	 cells)	 consist	of	an	extracellular	domain	 specific	 for	CD19	on	B-NHL	cells	and	





results	are	currently	evaluated	 for	 treatment	of	other	B-cell	malignancies,	 including	B-NHL	
[40].	Future	research	is	required	to	determine	the	consequences	of	targeting	the	BCR	complex	









prevent	 autoimmunity	 (reviewed	 in	 [42]).	 More	 specifically,	 these	 checkpoints	 play	 an	








gained	 more	 attention	 in	 the	 B-cell	 lymphoma	 field	 (Figure	 1d)	 (reviewed	 in	 [42]),	 and	
nivolumab	has	recently	been	approved	by	the	FDA	for	the	treatment	of	relapsed/refractory	
Hodgkin	lymphoma	due	to	promising	clinical	results	[44].	
For	 DLBCL,	 promising	 clinical	 results	 have	 been	 obtained	 with	 the	 anti-PD-1	mAbs	
pidilizumab	and	nivolumab	 [45,46],	 and	both	anti-PD-1	and	anti-PD-L1	mAbs	are	 currently	

























abundance	 on	 mature	 B	 cells,	 and	 is	 absent	 in	 earlier	 stages	 of	 B-cell	 development	 and	
decreased	on	plasma	cells	[54,55].	This	pattern	is	also	reflected	in	different	B-cell	lymphomas:	
CD37	is	mostly	expressed	on	B-cell	malignancies	derived	from	mature	B	cells	(although	~50%	










Nowadays	 several	 different	 antibody-based	 CD37-targeting	 approaches	 are	 under	
investigation	in	phase	I	and	II	trials	for	chronic	lymphocytic	leukemia	(CLL)	and	refractory	or	
relapsed	 NHL	 patients	 (reviewed	 in	 [61]	 and	 see	 https://clinicaltrials.gov/)	 (Figure	 1e).	
Otlertuzumab	(TRU-016),	a	humanized,	antibody-derived	CD37-targeting	peptide,	is	closest	to	
general	clinical	application	in	B-cell	malignancies.	In	a	randomized	phase	II	study,	relapsed	CLL	





internalized,	which	 has	 led	 to	 the	 generation	 of	 novel	 anti-CD37	 agents	 coupled	 to	 toxins	
(IMGN529,	 an	 anti-CD37	 antibody	 conjugated	 to	 an	 anti-microtubule	 agent)	 [64]	 and	
radioactive	 labels	 (177Lu-tetulomab)	 [65].	 Both	 agents	 showed	 promising	 results	 in	 NHL	
xenograft	mouse	models	 [64,65].	Moreover,	 177Lu-tetulomab	was	 internalized	with	 higher	
efficiency	 than	 177Lu-rituximab	 complexes	 in	 vitro	 [65],	 and	 IMGN529	 showed	 increased	
activity	compared	to	rituximab	or	CVP	chemotherapy	in	a	FL-derived	xenograft	mouse	model	
[64].	A	phase	I	clinical	trial	completed	in	July	2016	studied	IMGN529	in	relapsed/refractory	
NHL	 and	 CLL	 patients	 (NCT01534715),	 and	 several	 phase	 I/II	 clinical	 studies	 to	 test	 177Lu-
tetulomab	(Betalutin)	are	currently	including	NHL	patients	(https://clinicaltrials.gov/).	
Furthermore,	new	 insights	 into	the	function	of	CD37	have	prompted	the	 interest	 in	
combination	 strategies.	 CD37	 is	 important	 for	 the	 survival	 of	 IgG1-secreting	 plasma	 cells	
through	the	membrane	organization	of	α4β1	integrins,	and	subsequent	activation	of	the	AKT	
signaling	pathway	[66].	The	intracellular	tails	of	CD37	can	be	tyrosine	phosphorylated,	leading	
to	 the	 initiation	 of	 apoptotic	 signaling	 via	 the	 N-terminal	 immunoreceptor	 tyrosine-based	
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inhibition	motif	 (ITIM)-like	 domain,	 and	opposite	 survival	 signaling	 via	 its	 C-terminal	 ITAM	






independent	of	 the	 International	Prognostic	 Index	 (IPI)	 [56,57].	The	underlying	mechanism	
involves	enhanced	activation	of	the	IL-6	signaling	pathway	in	CD37-negative	lymphomas	[56].	











CD82	 on	 a	 lymphoma	 B-cell	 line.	 In	 addition,	 confocal	 microscopy	 [70]	 and	 co-
immunoprecipitation	 experiments	 [71]	 revealed	 that	 CD20	 also	 clusters	 with	 the	 BCR	 in	




and	 is	 subsequently	 internalized	 [70].	A	direct	 interaction	between	CD20	and	the	BCR	was	




although	 CD37	 was	 not	 studied.	 Recently,	 we	 discovered	 that	 both	 protein	 and	 mRNA	
expression	of	CD20	and	CD37	on	lymphoma	B	cells	are	correlated	[57].	Although	this	is	in	line	
with	 the	 inferior	 outcome	 of	 CD37-negative	 DLBCL	 patients	 upon	 R-CHOP	 therapy,	 the	
prognostic	 significance	 of	 CD37	 seems	 independent	 of	 CD20	 mRNA	 levels	 [57].	 Further	
research	is	necessary	to	verify	a	possible	direct	interaction	and	co-expression	patterns	of	CD37	
and	CD20	in	B-NHL	cases.	
	 These	 studies	 indicate	 that	 the	 organization	 of	 the	 B-cell	 membrane	 is	 shaped	 by	
dynamic	protein-protein	interactions	that	are	subject	to	change	upon	B-cell	activation.	This	
protein	 organization	 is	 not	 only	 important	 for	 B-cell	 function	 but	 also	 for	 the	 efficacy	 of	
membrane-targeted	 therapies,	 as	 illustrated	by	 clustering	of	CD20	upon	 rituximab	binding	
[18].	 Likewise,	 CD37-targeting	using	 SMIP-016	 resulted	 in	 translocation	 into	microdomains	
which	was	required	for	efficient	tumor	cell	apoptosis	[63].	On	lymphoma	B	cells,	changes	in	
membrane	 protein	 expression	 (e.g.	 absence	 of	 CD37)	 or	 protein	 clustering	 (e.g.	
conformational	 changes	of	 the	BCR	upon	binding	of	 self-antigens),	will	 change	 the	protein	
organization	and	interactions	at	the	plasma	membrane.	Based	on	these	studies	we	propose	
that	the	changed	cell	surface	protein	landscape	of	lymphoma	B	cells	has	consequences	for	the	
efficacy	 and	 application	 of	 membrane-targeted	 therapies	 (Figure	 2).	 Moreover,	 targeted	






Many	 patients	 with	 B-NHL	 still	 face	 treatment	 failure	 or	 relapse	 upon	 standard	 therapy	
emphasizing	the	urgent	need	for	new	treatment	options.	The	plasma	membrane	is	the	most	
easily	accessible	part	of	the	tumor	cell,	and	exposes	a	variety	of	different	proteins	which	may	




	 Membrane	 proteins	 interact	 with	 each	 other	 and	 thereby	 facilitate	 various	 cell	
biological	processes,	including	initiation	of	downstream	signaling.	B-cell	activation	will	affect	
these	 protein	 interactions	 through	 induction	 of	 new	 interactions,	 more	 clustering,	 or	
alternatively	by	preventing	specific	interactions.	Evidence	is	accumulating	that	lymphoma	B	
cells	contain	aberrant	cell	surface	protein	expression	and	organization	which	has	important	
























































































































































































































































Figure	 1.	 Current	 and	 novel	 membrane-targeted	 therapies	 in	 B-cell	 lymphoma.	 (a)	
Membrane	proteins	used	in	and	explored	for	lymphoma-targeted	therapy.	Left	to	right:	CD20;	
BCR	with	 its	signaling	proteins	CD79α/β;	CD19;	PD-L1;	tetraspanin	CD37	with	the	IL-6R.	(b)	
Targeting	CD20	using	mAb	 (e.g.	 rituximab)	will	 cluster	CD20	proteins	 leading	 to	 tumor	cell	
death	via	CDC,	ADCC	and/or	direct	apoptosis.	(c)	In	chronic	active	BCR	signaling	(i),	binding	of	
(self-)antigens	 to	 the	 BCR	 triggers	 recruitment	 of	 Syk	 to	 the	 phosphorylated	 (p-)ITAMs	 of	
CD79α/β,	which	leads	to	translocation	of	PI3K	to	CD19.	Subsequently,	BTK	is	activated	which	
initiates	NF-κB	activation	via	the	CARMA1-BCL10-MALT1	complex	resulting	 in	 lymphoma	B-
cell	 survival.	 In	 tonic	 BCR	 signaling	 (ii),	 constitutive	 activation	of	 PI3K	 in	 absence	of	 (self-)	
antigens	results	in	continuous	signaling	via	AKT	pathway	and	lymphoma	cell	survival.	Novel	
anti-idiotype	therapy	strategies	can	directly	target	the	BCR.	Syk,	PI3K	and	BTK	can	be	inhibited	






















results	 in	 CD20	 dissociation	 and	 redistribution,	 and	 anti-CD20	 targeted	 therapy	 using	
rituximab	 induces	CD20	clustering.	These	data	support	a	model	 in	which	 the	microdomain	







The	plasma	membrane	 is	 composed	of	multiple	different	proteins	and	 lipids	 that	are	non-





lipid	 rafts	 and	 tetraspanin-enriched	 microdomains	 (TEMs)	 [75].	 Lipid	 rafts	 were	 originally	
identified	as	membrane	fractions	that	are	insoluble	in	the	strong	detergent	Triton	X-100	[76],	
hence	 they	 are	 also	 defined	 as	 detergent-resistant	membrane	 domains	 (DRMs).	 They	 are	
enriched	 in	 densely	 packed	 sphingolipids	 and	 cholesterol,	 and	 harbor	










Tetraspanins	 are	 a	 family	 of	 four-transmembrane	 proteins	 involved	 in	 plasma	membrane	
organization	[79,82].	The	mammalian	tetraspanin	superfamily	consists	of	33	members,	which	
are	expressed	on	almost	all	cells	and	tissues	[83].	Tetraspanins	consist	of	four	transmembrane	
domains,	 a	 short	 extracellular	 loop	 (EC1),	 a	 large	 extracellular	 loop	 (EC2)	 containing	 a	
conserved	CCG	region,	a	small	intracellular	loop	and	two	short	intracellular	tails	[84],	and	S.	
van	Deventer	 et	 al.,	 in	 press].	Despite	 its	 similar	 structure,	 CD20	 cannot	be	 classified	 as	 a	
genuine	tetraspanin	protein,	since	it	lacks	the	conserved	CCG	region	in	the	large	extracellular	
loop	[85].	The	EC2	and	transmembrane	domains	are	involved	in	the	formation	of	tetraspanin-
enriched	microdomains	 (TEMs)	 by	 lateral	 associations	 with	 interaction	 partners,	 including	
other	 tetraspanins	 and	 integrins	 [78–80].	 Their	 short	 intracellular	 tails	 can	 interact	 with	
cytosolic	signaling	molecules	(e.g.	PKC,	Pi4K,	Rac)	[63,79],	and	S.	van	Deventer	et	al.,	in	press].	
Through	 their	multiple	 interaction	 partners,	 tetraspanins	 are	 involved	 in	 different	 cellular	
processes	 including	 survival,	 proliferation,	 adhesion	 and	 migration	 [78].	 Recently,	 several	
studies	have	shown	that	tetraspanins	contribute	to	cancer	development	and	metastasis,	and	
tetraspanin	 expression	 has	 been	 associated	 with	 patient	 outcome	 [56,86].	 Therefore,	
tetraspanins	 are	 interesting	 targets	 for	 cancer	 therapy,	 and	 different	 (pre-)clinical	 studies	







Antibody-dependent	 cell-mediated	 cytotoxicity:	 Induction	 of	 cell	 death	 via	 binding	 of	 an	
antibody	to	its	cell	surface	target.	The	Fc	tail	of	the	antibody	engages	Fc	receptor-expressing	
immune	 cells,	 like	NK	 cells	 and	macrophages,	 that	will	 kill	 the	 antibody-bound	 target	 (i.e.	
tumor)	cell.	
Burkitt	 lymphoma:	An	 aggressive	 type	 of	 B	 cell	 non-Hodgkin	 lymphoma	 characterized	 by	
deregulation	of	the	MYC	proto-oncogene.		
CHOP:	Abbreviation	for	Cyclophosphamide	–	Doxorubicin	(Hydroxydaunorubicin)	–	Vincristine	
(Oncovin)	 –	 Prednisone.	A	 chemotherapy	 cocktail	mostly	 used	 to	 treat	 B-cell	 non-Hodgkin	
lymphoma	patients.	Often	used	in	combination	with	anti-CD20	mAb	rituximab	(R-CHOP).	
Class	 switch	 recombination:	 The	process	 in	which	 the	 isotype	or	 class	 of	 immunoglobulin	
produced	by	the	B	cell	is	switched;	e.g.	from	IgM	to	IgG.	This	occurs	via	genomic	changes	in	
the	constant	region	of	the	immunoglobulin	heavy	chain.	






Hodgkin	 lymphoma,	 accounting	 for	 approximately	one	 third	of	 all	 non-Hodgkin	 lymphoma	
cases.		




Germinal	 center:	 area	 in	 the	 B-cell	 follicles	 of	 secondary	 lymphoid	 tissues	 where	 B-cell	
proliferation,	class	switch	recombination,	somatic	hypermutation	and	selection	take	place.		
Somatic	hypermutation:	The	process	in	which	the	immunoglobulin-encoded	DNA	of	mature	
B	cells	is	subjected	to	the	introduction	of	random	point	mutations.	These	modifications	occur	
in	the	variable	region	of	the	immunoglobulin	gene	resulting	in	affinity	maturation	(increased	
affinity	BCR).	
